Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.
NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%). Protection did not correlate with CS repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell depletion. Protection was not enhanced by modification of the subcellular localization of CSP. These results suggest the potential of poxvirus-based vectors for the development of vaccine candidates for human malaria.
Lanar
D E
DE
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.
Tine
J A
JA
de Taisne
C
C
Seguin
M C
MC
Cox
W I
WI
Winslow
J P
JP
Ware
L A
LA
Kauffman
E B
EB
Gordon
D
D
Ballou
W R
WR
Paoletti
E
E
Sadoff
J C
JC
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D006801:Humans; D007111:Immunity, Cellular; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D010962:Plasmodium berghei / Q000235:genetics / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology*; D016052:Protozoan Vaccines / Q000235:genetics / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014613:Vaccines, Attenuated / Q000235:genetics / Q000494:pharmacology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000494:pharmacology*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
D000913:Antibodies, Protozoan; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D011994:Recombinant Proteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; C041595:circumsporozoite protein, Protozoan